Delving into the Latest Updates on JNJ-47910382 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Hepatitis C virus NS 5 protein

Mechanism

Hepatitis C virus NS 5 protein inhibitors

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication-

Inactive Indication

Chronic hepatitis C genotype 1Hepatitis C

Originator Organization

Janssen Global Services LLC

Active Organization-

Inactive Organization

Johnson & Johnson (Ireland) Ltd.

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to assess the relative bioavailability (the degree to which the study medication becomes available in the blood circulation) of JNJ-47910382, given as an uncoated tablet and as a suspension, after a single oral dose of 200 mg in healthy adult participants under fed conditions.

Start Date01 Jul 2012

Sponsor / Collaborator

Johnson & Johnson (Ireland) Ltd.

NCT01586325 / TerminatedPhase 1

A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Trial in Asian Genotype 1 Chronic HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of JNJ-47910382 Given in Different Doses and Dose Regimens

The purpose of this study is to determine the safety, tolerability, pharmacokinetics (how a drug is absorbed and distributed in the body), and intrinsic antiviral activity of JNJ-47910382 after 5 consecutive days of administration in chronic, hepatitis C virus (HCV)-genotype-1-infected patients at different doses and dose regimens.

Start Date25 May 2012

Sponsor / Collaborator

Johnson & Johnson (Ireland) Ltd.

100 Clinical Results associated with JNJ-47910382

Login to view more data

100 Translational Medicine associated with JNJ-47910382

Login to view more data

100 Patents (Medical) associated with JNJ-47910382

Login to view more data

100 Deals associated with JNJ-47910382

Login to view more data